Composition beneficial to improvement of brain cognition, memory and sleep and used for preventing and improving Alzheimer's disease

Abstract

The invention provides a composition beneficial to improvement of brain cognition, memory and sleep and prevention and improvement of Alzheimer's disease, and belongs to the technical field of health food. The composition comprises L-alpha-glycerophosphorylcholine (GPC), phosphatidylserine (PS), docosahexaenoic acid (DHA), tea leaf theanine (L-theanine), vitamin B groups, vitamin D3 and the like, and is prepared into a health care product, a dietary supplement, a functional food, a medical food or a nutritional supplement by adopting the existing technology. The traditional Chinese medicine composition has the effects of effectively nourishing nerve cells, improving the brain sensitivity and improving the cognitive function. The composition is particularly directed at age-related cognitive decline and neurodegenerative diseases. Repair and regeneration of nerve cells can be promoted, the transmission efficiency of neural signals is enhanced, and the overall working efficiency of the brain is improved. Daily life challenges caused by cognitive decline can be relieved, and individual life quality can be improved.

Description

Technical Field

[0001] The present invention relates to a composition for improving brain cognition, memory, sleep and preventing and improving Alzheimer's disease in an individual. Background Art

[0002] With the current fast-paced working environment and lack of awareness of healthy diet, as well as the increasing aging of society, the deterioration of brain cognitive function has become a social phenomenon that cannot be ignored. Cognitive deterioration of the brain not only affects the quality of life of individuals, but also brings a heavy burden to families and society. Among them, Alzheimer's disease, as a typical representative of cognitive deterioration, is gradually becoming a global public health challenge. In daily life, cognitive deterioration of the brain manifests itself in symptoms such as memory loss, inattention, decreased language ability, and decreased sleep quality. These changes make it difficult for patients to complete daily affairs independently and even affect social activities. As the disease progresses, patients may gradually lose the ability to take care of themselves, which is not only a torture for the patients themselves, but also brings huge psychological pressure and economic burden to family members.

[0003] The degeneration of brain cognitive function is a complex process involving multiple factors and mechanisms. It is a common phenomenon that cognitive function gradually declines with age. People's core cognitive abilities, including processing speed, reasoning, episodic memory, and spatial visualization, begin to gradually decline after the age of 30. This decline may be related to synaptic plasticity and degeneration of neurons, changes in neurotransmitters, changes in intracellular calcium homeostasis, epigenetic changes, cell aging and autophagy, oxidative stress, changes in mitochondrial function, and inflammation.

[0004] The main clinical manifestations of Alzheimer's disease (AD) are cognitive impairment, decreased ability to live daily, non-cognitive neuropsychiatric symptoms, language expression disorders, disorientation, visual and spatial disorders, and even personality changes, as well as behavioral and mental abnormalities. The main pathological features are β-amyloid deposition, neurofibrillary tangles, neuronal loss and brain atrophy, synaptic and neuronal loss, reactive gliosis, and neuroinflammation. The therapeutic drugs for Alzheimer's disease (AD) mainly include the following categories: cholinesterase inhibitors (first-line drugs for the treatment of mild to moderate AD, mainly including donepezil, rivastigmine, galantamine, etc.), glutamate receptor antagonists (memantine) and other drugs. With the continuous development of related drugs, rivastigmine bitartrate oral solution and new monoclonal antibody drugs (such as lecanemab and lecanemab) are also constantly used in clinical practice.

[0005] In order to effectively deal with the deterioration of brain cognitive function, in addition to drug treatment, early prevention and early intervention countermeasures are also highly valued. Studies have found that a healthy diet, especially rich in glycerophosphocholine (L-α-GPC), phosphatidylserine (PS), docosahexaenoic acid (DHA), omega-3 fatty acids, vitamin B family and some other antioxidants, is believed to provide nutrients needed by the brain, maintain the normal function of the nervous system, improve sleep quality, improve memory, and delay the progression of Alzheimer's disease. If functional foods that can be safely taken for a long time and have the effects of improving brain cognition, memory, sleep quality and delaying the progression of Alzheimer's disease can be developed, there is also a huge market prospect.

[0006] Patent CN 117442640 A discloses a drug formula for improving cardiovascular and cerebrovascular diseases and sleep quality and preventing Alzheimer's disease, wherein the main formula includes γ-aminobutyric acid, neuraminic acid, docosahexaenoic acid, phosphatidylserine, zinc gluconate, vitamin B1 and vitamin B2. Patent CN 118415342 A discloses a phosphatidylserine multidimensional nutrient composition for improving memory, wherein the main composition includes phosphatidylserine, γ-aminobutyric acid, kudzu root extract, taurine and the like. Patent CN 117918425 A discloses a neuraminic acid composition for improving memory and learning function and its preparation method. The composition includes various nutrients such as neuraminic acid, DHA, arachidonic acid and the like. Patent CN 115669929 A discloses a functional food for assisting in improving memory, which includes β-nicotinamide mononucleotide (NMN) and La-glycerophosphocholine (a-GPC). Patent CN 105682654 A discloses that the present invention provides a composition for improving cognitive performance in a subject, which comprises a combination of a choline source (such as La-glycerophosphocholine), a magnesium source and an L-tryptophan source. With the continuous research on brain function degeneration and the application of new functional foods, these prior arts have highlighted serious deficiencies.

[0007] This patent discloses a composition that is beneficial to improving brain cognition, memory, sleep, and for preventing and improving Alzheimer's disease, characterized in that it contains at least one or more of glycerophosphocholine (L-α-GPC), phosphatidylserine (PS), docosahexaenoic acid (DHA), tea theanine, vitamin B family, and vitamin D3. The patent makes up for the shortcomings of the prior art. Glycerol phosphocholine (L-α-GPC) can penetrate the blood-brain barrier and provide the necessary choline for the synthesis of acetylcholine and phospholipids. Acetylcholine is an important neurotransmitter responsible for memory, learning, normal cognitive function, and human growth hormone secretion. Glycerol phosphocholine (L-α-GPC) is decomposed into 3-phosphoglycerol and choline in the brain, and is the most efficient acetylcholine supply depot, which enhances memory and improves thinking by promoting the synthesis and release of acetylcholine in the brain. At the same time, L-α-GPC promotes the synthesis of phosphoinositide, which is an important component of the cell membrane. Its synthesis helps maintain the integrity and function of the cell membrane, enables cells to transmit signals more effectively, enhances the stability and fluidity of the cell membrane, and thus improves the body's mental agility.

[0008] Phosphatidylserine (PS) is one of the main components of cell membranes and can enhance the stability of cell membranes. During brain damage, cell membranes are damaged, leading to disordered exchange of substances inside and outside the cells. Supplementation of phosphatidylserine can repair damaged cell membranes and restore their normal functions, thereby promoting normal cell metabolism and signal transduction. Docosahexaenoic acid (DHA) is an important component of the cell membrane of brain neurons. It is essential for the growth and connection of nerve cells and plays a key role in brain health and development. Tea theanine can reduce the damage to nerve cells, relieve the symptoms of cerebral ischemia, and play a protective role against cerebral ischemia-reperfusion injury by affecting the expression of hippocampal BDNF mRNA and Bcl-2 mRNA. At the same time, theanine is rich in phenolic hydroxyl groups, which can effectively remove free radicals in the human body and prevent free radicals from damaging human cells, thereby playing an antioxidant and anti-aging role; vitamin B family can reduce homocysteine ​​levels, which is beneficial to reduce the risk of Alzheimer's disease and slow down cognitive decline. Vitamin D3 deficiency may cause brain neuron damage and affect cognitive function; Vitamin D3 can induce the expression of neurotrophic factors that promote neuron growth and differentiation, such as nerve growth factor (NGF) and neurotrophic factor receptor p75 (NTR). Vitamin D3 has anti-inflammatory and antioxidant effects, which can reduce brain inflammation and reduce the risk of dementia. The purpose of the present invention is to overcome the shortcomings of the above-mentioned prior art, protect the function of the brain nervous system from multiple dimensions such as the composition of neuronal cell membranes, the synthesis of acetylcholine, nutritional requirements, reducing cell damage, reducing external factors of cell damage, and removing free radicals in the human body, and disclose a composition that is beneficial to improving brain cognition, memory, sleep, and preventing and improving Alzheimer's disease, and the raw materials used are all food grade, which is a functional food that can be safely taken for a long time and has the effect of improving brain cognition, memory, sleep, and preventing and improving the process of Alzheimer's disease. Summary of the invention

[0009] The purpose of the present invention is to develop a composition with definite effects and convincing safety for improving brain cognition, memory, sleep and for preventing and improving Alzheimer's disease, so as to meet the needs of patients with Alzheimer's disease who are suitable for long-term use and can improve brain cognition, memory, sleep and for preventing and improving Alzheimer's disease.

[0010] After in-depth research and demonstration, the inventor of this patent unexpectedly concluded that a combination of glycerophosphocholine (L-α-GPC), phosphatidylserine (PS), docosahexaenoic acid (DHA), tea theanine, vitamin B family and vitamin D3 can effectively improve brain cognition, memory, sleep and prevent and improve Alzheimer's patients, thus completing the present invention. The composition of the present invention can be used to prepare health products, dietary supplements, functional foods, medical foods or nutritional supplements for improving brain cognition, memory, sleep and preventing and improving the brain health of Alzheimer's patients.

[0011] Specifically, the present invention is achieved by: The present invention provides a composition for improving brain cognition, memory, sleep and for preventing and improving the brain health of patients with Alzheimer's disease, characterized by containing a combination of ingredients such as glycerophosphocholine (L-α-GPC), phosphatidylserine (PS), docosahexaenoic acid (DHA), tea theanine, vitamin B and vitamin D, as well as auxiliary materials and excipients that are acceptable in the fields of health products, dietary supplements, functional foods, medical foods or nutritional supplements.

[0012] The composition and dosage range of the active ingredient combination are as follows: Glycerophosphocholine (La-GPC) 50 to 1000 mg / person / day Phosphatidylserine (PS) 20 to 600 mg / person / day Docosahexaenoic acid (DHA) 20 to 1000 mg / person / day Tea Theanine (L-Theanine) 50 to 1000 mg / person / day Vitamin B1 0.2 mg to 10 mg / person / day Vitamin B2 0.2 mg to 10 mg / person / day Vitamin B6 0.3 mg to 300 mg / person / day Vitamin B9 0.1 mg to 1 mg / person / day Vitamin B12 0.1 mg to 1 mg / person / day Vitamin D3 0.002 mg to 0.02 mg / person / day Preferably, the composition comprises at least one or more of glycerophosphocholine (L-α-GPC), phosphatidylserine (PS), docosahexaenoic acid (DHA), tea theanine, B vitamins and vitamin D3.

[0013] Since the raw materials of the composition of the present invention are all food grade, it is suitable for development into various types of health products, dietary supplements, functional foods, medical foods or nutritional supplements, and can be prepared into tablets, hard capsules, soft capsules, soft candies (candies), solid beverages, liquid beverages and any other forms of oral consumption. The health products, dietary supplements, functional foods, medical foods or nutritional supplements of the present invention, in addition to the above-mentioned composition of the present invention, may also contain other edible auxiliary materials or food additives. As food additives that can be used and meet relevant standards, they should be food additives that meet the standards of the National Food Safety Standard Food Additives Use Standard of the People's Republic of China (GB 2760-2024).

[0014] As the preferred form of the health care products, dietary supplements, functional foods, medical foods or nutritional supplements of the present invention, it can be preferably soft candy (candy). The mode of making the composition of the present invention into soft candy (candy) is not particularly limited, and known methods can be used, for example, the preparation of the composition of the present invention, adding edible auxiliary materials and the like to mix, and carrying out the process of molding, solidification, demoulding and packaging. As the auxiliary materials of edible soft candy (candy), including but not limited to, such as sweeteners, grease, dairy products, acidulants and gelling agents, gelling agents can be cited including but not limited to, such as starch and modified starch, agar, gelatin, pectin, carrageenan, konjac gum, gum arabic, linseed gum, coagulated polysaccharide, pullulan, gellan gum, etc. The auxiliary materials used can be appropriately added as long as they meet food standards (such as the People's Republic of China "National Food Safety Standard Food Additive Use Standard" (GB2760-2024)).

[0015] As the preferred form of the functional food of the present invention, from the perspective of strong food appearance and high acceptance, the composition of the present invention can also be made into the form of tablets. As the dosage form of tablets, including but not limited to ordinary tablets, buccal tablets, orally disintegrating tablets, enteric-coated tablets, etc., the preparation method is not particularly limited, and known methods can be used. For example, the granulation of the composition of the present invention, adding edible auxiliary materials and the like mixed, the process of tableting. As edible auxiliary materials, starch, lactose, microcrystalline cellulose, methylcellulose, sucrose, oligofructose, tea powder, salt, steviol glycosides, sorbitol, vitamin C, etc. can be cited, but not limited to these, as long as it is in accordance with food standards (such as the People's Republic of China "Food Safety National Standard Food Additives Use Standard" (GB 2760-2024)) auxiliary materials can be appropriately added.

[0016] As a preferred form of the functional food of the present invention, from the perspective of strong food appearance and high acceptance, the composition of the present invention can also be made into a food oral liquid. The dosage form of the liquid preparation for oral food is solution, syrup or suspension. In the preparation method of these liquid preparations, the dispersion medium is generally water, and the non-water-soluble excipients are natural or semi-synthetic oils such as almond oil. Other permitted fillers may also include sorbitol, hydrogenated edible oil, methylcellulose; preservatives such as methyl or propyl P-phenol; emulsifiers such as lecithin, gum arabic; artificial coloring or sweeteners.

[0017] As for the amount of consumption, it should be determined according to the patient's age, weight, health status and dosage form. The recommended dosage per person / day includes 50mg to 1000mg of glycerophosphocholine (L-α-GPC), 20mg to 600mg of phosphatidylserine (PS), 20mg to 1000mg of docosahexaenoic acid (DHA), 50mg to 1000mg of tea theanine, 0.2mg to 10mg of vitamin B1, 0.2mg to 10mg of vitamin B2, 0.3mg to 300mg of vitamin B6, 0.1mg to 1mg of vitamin B9, 0.1mg to 1mg of vitamin B12, and 0.002mg to 0.02mg of vitamin D3. However, since the raw materials of the present invention are all very safe, those skilled in the art can appropriately increase or decrease the effective amount of each component according to individual needs.

[0018] Compared with the prior art, the composition of the present invention has the following obvious advantages: the composition of glycerophosphocholine (L-α-GPC) and phosphatidylserine (PS) used in the composition developed by the present invention can not only promote the synthesis of acetylcholine by providing choline, but also maintain the integrity of the membrane structure. The two have a specific synergistic effect, jointly enhance the transmission efficiency of nerve signals, promote the repair and regeneration of nerve cells, improve brain cognitive function, and delay the progression of neurodegenerative diseases; the composition of glycerophosphocholine (L-α-GPC), phosphatidylserine (PS), docosahexaenoic acid (DHA), tea theanine, vitamin B group and vitamin D used in the composition developed by the present invention adopts a scientific formula to obtain the synthesis of acetylcholine from neuronal cells. The composition of the cell membrane, the synthesis of acetylcholine, nutritional requirements, reducing cell damage, reducing external factors of cell damage, removing free radicals in the human body and other dimensions protect neuronal cells. In the composition, there is a specific effect of mutual synergy, promoting absorption and complementing each other to protect nerves. The raw materials of the composition developed by the present invention are all food. It is a composition with clear effects and convincing safety that effectively improves brain cognition, memory, sleep and is used to prevent and improve the brain health of Alzheimer's patients. The effects of various nutrients have been verified in the market, and its composition is particularly suitable for long-term use. It can be used to improve brain cognition, memory, sleep and prevent and improve the progress of Alzheimer's disease, so it has broad market prospects. DETAILED DESCRIPTION To make the purpose, technical scheme and advantages of the embodiments of the present invention clearer, the technical scheme in the embodiments of the present invention will be clearly and completely described below. Each example provided is for explanation rather than limitation of the present invention. In fact, it is obvious to those skilled in the art that various modifications and changes can be made to the present invention without departing from the scope or spirit of the present invention. For example, the features illustrated or described as part of one embodiment can be used in another embodiment to produce a further embodiment. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention. If the specific conditions are not indicated in the embodiments, they are carried out according to conventional conditions or the conditions recommended by the manufacturer. The raw materials, auxiliary materials or instruments used without indicating the manufacturer are all conventional products that can be purchased commercially.

[0020] The features and performance of the present invention are further described in detail below in conjunction with the embodiments. Example 1

[0021] This embodiment provides a composition that is beneficial to improving brain cognition, memory, sleep, and preventing and improving Alzheimer's disease. The raw materials thereof include, in terms of human / day dosage: wherein the composition includes the following: Glycerophosphocholine (La-GPC) 50 mg / person / day Phosphatidylserine (PS) 20 mg / person / day Example 2

[0022] This embodiment provides a composition that is beneficial to improving brain cognition, memory, sleep, and preventing and improving Alzheimer's disease. The raw materials thereof include, in terms of human / day dosage: wherein the composition includes the following: Glycerophosphocholine (La-GPC) 600 mg / person / day Phosphatidylserine (PS) 300 mg / person / day Example 3

[0023] This embodiment provides a composition that is beneficial to improving brain cognition, memory, sleep, and preventing and improving Alzheimer's disease. The raw materials thereof include, in terms of human / day dosage: wherein the composition includes the following: Glycerophosphocholine (La-GPC) 1000 mg / person / day Phosphatidylserine (PS) 600 mg / person / day Example 4

[0024] This embodiment provides a composition that is beneficial to improving brain cognition, memory, sleep, and preventing and improving Alzheimer's disease. The raw materials thereof include, in terms of human / day dosage: wherein the composition includes the following: Glycerophosphocholine (La-GPC) 50 mg / person / day Phosphatidylserine (PS) 200 mg / person / day Docosahexaenoic acid (DHA) 20 mg / person / day Tea Theanine (L-Theanine) 50 mg / person / day Example 5

[0025] This embodiment provides a composition that is beneficial to improving brain cognition, memory, sleep, and preventing and improving Alzheimer's disease. The raw materials thereof include, in terms of human / day dosage: wherein the composition includes the following: Glycerophosphocholine (La-GPC) 600 mg / person / day Phosphatidylserine (PS) 300 mg / person / day Docosahexaenoic acid (DHA) 200 mg / person / day Tea Theanine (L-Theanine) 200 mg / person / day Example 6

[0026] This embodiment provides a composition that is beneficial to improving brain cognition, memory, sleep, and preventing and improving Alzheimer's disease. The raw materials thereof include, in terms of human / day dosage: wherein the composition includes the following: Glycerophosphocholine (La-GPC) 1000 mg / person / day Phosphatidylserine (PS) 600 mg / person / day Docosahexaenoic acid (DHA) 1000 mg / person / day Tea Theanine (L-Theanine) 1000 mg / person / day Example 7

[0027] This embodiment provides a composition that is beneficial to improving brain cognition, memory, sleep, and preventing and improving Alzheimer's disease. The raw materials thereof include, in terms of human / day dosage: wherein the composition includes the following: Glycerophosphocholine (La-GPC) 50 mg / person / day Phosphatidylserine (PS) 20 mg / person / day Docosahexaenoic acid (DHA) 20 mg / person / day Tea Theanine (L-Theanine) 50 mg / person / day Vitamin B1 0.2 mg / person / day Vitamin B2 0.2 mg / person / day Vitamin B6 0.2 mg / person / day Vitamin B6 0.3 mg / person / day Vitamin B9 0.1 mg / person / day Vitamin B12 0.1 mg / person / day Vitamin D3 0.002mg / person / day Example 8

[0028] This embodiment provides a composition that is beneficial to improving brain cognition, memory, sleep, and preventing and improving Alzheimer's disease. The raw materials thereof include, in terms of human / day dosage: wherein the composition includes the following: Example 9

[0029] This embodiment provides a composition that is beneficial to improving brain cognition, memory, sleep, and preventing and improving Alzheimer's disease. The raw materials thereof include, in terms of human / day dosage: The components include the following: Glycerophosphocholine (La-GPC) 1000 mg / person / day Phosphatidylserine (PS) 600 mg / person / day Docosahexaenoic acid (DHA) 1000 mg / person / day Tea Theanine (L-Theanine) 1000 mg / person / day Vitamin B1 10 mg / person / day Vitamin B2 10 mg / person / day Vitamin B6 10 mg / person / day Vitamin B6 300 mg / person / day Vitamin B9 1 mg / person / day Vitamin B12 1 mg / person / day Vitamin D3 0.02mg / person / day In summary, the nutritional components determined by the metabolome and behavioral analysis of the present invention are: glycerophosphocholine (L-α-GPC), phosphatidylserine (PS), docosahexaenoic acid (DHA), tea theanine, vitamin B family and vitamin D3. The above raw material components complement each other and have a specific synergistic effect, so that the present invention has the effect of effectively improving brain cognition, memory, sleep, and preventing and improving the brain health of patients with Alzheimer's disease.

[0030] The application of the present invention preferably selects a composition for improving brain cognitive function or preventing / improving the brain health of Alzheimer's patients, but is not limited to, and also includes but is not limited to other applications: enhancing memory and cognitive function, improving learning and information processing ability, resisting fatigue and enhancing physical fitness, relieving anxiety and stabilizing emotions, improving sleep quality, protecting nerves and anti-aging, improving cerebrovascular health, promoting neurotransmitter synthesis, increasing growth hormone secretion, maintaining normal brain function, and combating age-related cognitive decline, etc.

[0031] The test of the protective effect of the composition on nerves: The composition of different dosage groups was prepared according to the dosage of Examples 1-9, and the efficacy on Alzheimer's disease model mice was studied.

[0032] AD model establishment: The AD model was established by injecting exogenous harmful substances in combination with D-galactose and aluminum chloride to damage the learning and memory, cholinergic system, and the gene expression of β-amyloid precursor protein (APP), presenilin 1 (PS1), β-site APP endonuclease (BACE) in the brain, as well as the morphology of the hippocampus and cortex. The method was to inject D-galactose solution into the peritoneum of mice at a dose of 100 mg / kg / d, and gavage aluminum chloride solution at a dose of 10 mg / kg / d, and the model was established for 60 days continuously. The Morris water maze test (MWM) was used to determine the learning and memory ability of mice, and AD mice were screened. The normal group was injected with an equal amount of saline and gavaged with an equal amount of distilled water.

[0033] AD model mice were randomly divided into a blank group, different dose groups 1-9 in the example, and a normal group according to the random method in the animal grouping method, with 10 mice in each group, and were administered according to the following groups and doses. The blank group and the normal group were gavaged with an equal amount of distilled water. The different dose groups 1-9 were obtained according to the simplified body surface area conversion method (mouse dose = X mg / kg × 9.1) in the example. The prepared compositions of different doses were dispersed in warm water at 35-40° C. and then gavaged, wherein the administration time was 30 days. At the same time as the administration, each group continued to be administered with the modeling agent to avoid natural recovery.

[0034] Open field test: After grouping, the experimental mice were tested in an open box experiment. The experimental device of the open box experiment consists of two parts, an open box device and a recording device. The specifications of the open box used (length * width * height) are: 50cm*50cm*40cm; (provided by Shanghai Xinruan Information Technology Co., Ltd.). The top of the open box is connected to a camera, and the camera is connected to a computer to record the experimental results. The bottom of the open box is divided into 25 blocks of equal area using computer software, with 16 blocks around the open box as the peripheral area and 9 blocks in the center as the central area. Each animal is measured once, and each time lasts for 5 minutes. The open box memory experiment lasts for 5 days. On the 6th day of the experiment, the total distance traveled by each mouse in the open box and the time the mouse stayed in the peripheral area and the central area were recorded, and the proportion of peripheral time was calculated. After cleaning the open box each time, the next mouse will be tested.

[0035] Barnes maze test: After the open box experiment, the Barnes maze test was performed. The operation process of the Banes maze experiment was based on the Barnes method with slight adjustments. The Barnes maze consists of a circular platform with 20 holes and a small, lightless recessed chamber called a "target box" at the bottom of one of the holes. The original platform has a diameter of 92 cm and the hole has a diameter of 5 cm. A camera is installed above the maze and connected to a computer. At the beginning of each training session, the mouse is placed in the center of the maze and is free to choose to enter the small hole on the platform. Each training session lasts for 240 seconds, and the time taken by the mouse to enter the target box within 240 seconds (escape latency) is recorded. If the mouse does not enter the target box within 240 seconds, the escape latency is recorded as 240 seconds. The test lasts for 6 days, with the first 5 days being the maze memory test period. The escape latency and number of errors are recorded on the 6th day. After each mouse is finished, the maze is wiped with alcohol, and the Barnes maze is rotated, but the relative spatial position of the target box is not changed to prevent the mouse from finding the location of the target box through information such as smell. The results are shown in Table 1.

[0036] Table 1 Test results statistics

[0037] Results analysis: In the open field test, there was no significant difference in the physical fitness of mice in each group compared with the normal group in Examples 2, 3, 5, 6, 8, and 9, and the total distance walked was equivalent, and the peripheral time ratio was also equivalent, indicating that there was no significant difference in the mental state, memory, and body repair of mice and mice in the normal group after taking the composition containing Examples 2, 3, 5, 6, 8, and 9. Compared with the blank group, the total distance walked and the peripheral ratio of Examples 1, 4, and 7 were better than the blank group, and the mental state of mice in the low-dose group of Examples 1, 4, and 7 was also better than the blank group, indicating that the composition in the low-dose group of Examples 1, 4, and 7 improved the mental state, memory, and body repair of the blank group.

[0038] In the Barnes maze test, the latency and number of errors of Examples 1-9 were lower than those of the blank group, indicating that the learning and memory abilities and cognitive functions of the mice of Examples 1-9 were far superior to those of the blank group, the cognitive functions of the mice in the blank group were severely impaired, and the experimental data of Examples 2, 3, 5, 6, 8, and 9 were not significantly different from those of the normal group, that is, the learning and memory abilities and cognitive functions of the mice of Examples 2, 3, 5, 6, 8, and 9 were comparable to those of the mice in the normal group, indicating that the compositions of Examples 2, 3, 5, 6, 8, and 9 can effectively improve cognitive disorders and behavioral disorders in AD model mice and improve cognitive functions, proving that the invention can effectively protect nerves.

[0039] Comprehensive analysis shows that the combination containing glycerophosphocholine (L-α-GPC) and phosphatidylserine (PS) (Example 1) has a better experimental effect than the blank group, indicating that the combination of glycerophosphocholine (L-α-GPC) and phosphatidylserine (PS) has a promoting effect on the mental state, memory and body repair of AD model mice.

[0040] L-α-GPC can penetrate the blood-brain barrier and provide the necessary choline for the synthesis of acetylcholine and phospholipids. It is decomposed into 3-phosphoglycerol and choline in the brain, and is the most efficient acetylcholine supply depot. It enhances memory and improves thinking by promoting the synthesis and release of acetylcholine in the brain. At the same time, L-α-GPC promotes the synthesis of phosphoinositide, increases the amount of phospholipids in the brain, provides more phospholipid compounds for signal transmission in the central nervous system, enhances the stability and fluidity of cell membranes, and plays an important role in lipid metabolism, neuroprotection and cell signal transduction, thereby improving the body's mental agility.

[0041] PS is the main acidic phospholipid in the brain and is very important for maintaining normal brain memory, reaction and healthy emotions. It can affect the transmission of chemical information in the brain and help brain cells store and read data. It has a synergistic and complementary effect with glycerophosphocholine (L-α-GPC) in improving brain function and repairing brain damage, enhancing physical fitness and anti-fatigue, protecting nerve cells, enhancing memory and cognitive function, and improving learning and information processing ability in AD model mice.

[0042] By comparing the experimental results of Examples 4, 5, and 6 with those of Examples 1, 2, and 3, it can be concluded that the combination containing glycerophosphocholine (L-α-GPC), phosphatidylserine (PS), docosahexaenoic acid (DHA), and tea theanine is better than the combination containing only glycerophosphocholine (L-α-GPC) and phosphatidylserine (PS). The DHA in Examples 4, 5, and 6 has an important influence on the development and function of the brain and retina, and supplementing with PS can promote the absorption and utilization of each other. Tea theanine can increase the level of brain-derived neurotrophic factor and stimulate neurogenesis, improving cognitive function.

[0043] By comparing the experimental results of Implementation 7, 8, 9 with those of Examples 1, 2, and 3, it can be concluded that the combination containing glycerophosphocholine (L-α-GPC), phosphatidylserine (PS), docosahexaenoic acid (DHA), tea theanine, B vitamins and vitamin D3 is better than the combination containing only glycerophosphocholine (L-α-GPC) and phosphatidylserine (PS) in Example 1.

[0044] B vitamins and vitamin D3 are essential for the health of the nervous system. B vitamins can act as "starters" for other substances because they are involved in energy metabolism and the synthesis of neurotransmitters, which are essential for maintaining the normal function and metabolism of nerve cells. Vitamin D3 has a positive effect on neuromuscular function and brain health. B vitamins and vitamin D3 work together to promote the absorption and utilization of other nutrients, enhancing the overall effect, thereby supporting and enhancing the health of the nervous system.

[0045] Acute toxicology test: The toxicological safety evaluation of health food was carried out in accordance with the "Specifications for Toxicological Safety Evaluation Procedures and Test Methods for Health Foods", and the test results were as follows: the mixtures of the combinations of Examples 3, 6, and 9 were divided into three groups, with 20 SD rats (half male and half female) in each group, and each SD rat was fed at a dose of 10 g / kg, administered once, and observed for 14 consecutive days. No abnormalities were found in the general condition of the SD rats. The experimental results showed that the maximum tolerable dose of the composition for SD rats was greater than 10 g / kg, and no toxic reactions occurred, and it was non-toxic.

[0046] Experiment on learning and cognitive function: 40 volunteers were randomly selected for the experiment. Among them, the volunteers had not received any similar experiments, and had not taken drugs or health products related to improving brain cognition or memory. The volunteers were randomly divided into 4 groups, 10 people in each group, namely blank group, experimental group 1, experimental group 2, and experimental group 3. The gender composition, memory quotient mean and standard deviation of each group were basically the same, and the test was conducted using the double-blind method.

[0047] Test method: The volunteers in the blank group took one blank tablet orally every day, the volunteers in the experimental group 1 took one tablet of the drug prepared in Example 2 orally every day, the volunteers in the experimental group 2 took one tablet of the drug prepared in Example 5 orally every day, and the volunteers in the experimental group 3 took one tablet of the drug prepared in Example 8 orally every day. After taking it for 7 days, follow-up was conducted to record the taking situation of each group of volunteers. The test method was carried out according to the revised Wechsler scale, and the test content included 5 basic components: mind, recognition, association, picture and understanding. The details are shown in Table 2 below: Table 2 Test results on learning cognitive function Test items Blank group Experimental Group 1 Experimental Group 2 Experimental Group 3 Mind 30.14±3.31 31.34±4.23 31.75±4.15 32.82±4.07 Recognition 9.34±2.61 16.79±3.48 17.55±3.34 17.83±3.06 Lenovo 10.05±2.09 16.91±3.75 17.22±3.54 17.15±3.36 picture 8.79±2.78 16.14±3.48 17.24±3.37 16.82±3.18 understand 9.55±3.15 15.87±4.07 16.38±3.61 17.26±3.92 It can be seen from the results in the table that the volunteers took the composition preparations of Examples 2, 5, and 8 for 7 consecutive days, and compared with the blank group, the scores of the mental, recognition, association, picture and understanding tests were improved, indicating that the composition prepared by the patent of the present invention can effectively improve or enhance the learning cognition or memory ability of the test volunteers through the combination of multiple effective ingredients, the content of each ingredient and the mass ratio, and there is no adverse reaction in the body during the volunteers' taking.

[0048] It should be noted that the preferred embodiments given in the specification of this patent can also be implemented in many different forms and are not limited to the embodiments described in this specification. These embodiments are not intended to be additional limitations on the content of the present invention. The purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive. In addition, the above-mentioned technical features continue to be combined with each other to form various embodiments not listed above, which are all considered to be within the scope of the specification of the present invention; further, for ordinary technicians in this field, they can be improved or transformed according to the above description, and all these improvements and transformations should fall within the scope of protection of the claims attached to the present invention.

Claims

1. A composition that is beneficial to improving brain cognition, memory, sleep and for preventing and improving Alzheimer's disease, characterized in that It must contain at least a combination of 50-1000 mg of L-α-GPC and 20-600 mg of phosphatidylserine (PS) in a daily dosage per person, as well as excipients and excipients that are acceptable in the fields of health products, dietary supplements, functional foods, medical foods or nutritional supplements.

2. A composition according to claim 1 that is beneficial to improving brain cognition, memory, sleep and for preventing and improving Alzheimer's disease, characterized in that At least a combination of 50mg to 1000mg of L-α-GPC, 20mg to 600mg of phosphatidylserine (PS) and 20mg to 1000mg of docosahexaenoic acid (DHA) per person per day, and excipients and excipients that are acceptable in the fields of health products, dietary supplements, functional foods, medical foods or nutritional supplements.

3. A composition according to claim 1 that is beneficial to improving brain cognition, memory, sleep and for preventing and improving Alzheimer's disease, characterized in that At least one or a combination of glycerylphosphocholine (L-α-GPC) with a daily usage range of 50mg to 1000mg, phosphatidylserine (PS) of 20mg to 600mg, docosahexaenoic acid (DHA) of 20mg to 1000mg, and tea theanine of 50mg to 1000mg per person, as well as excipients and excipients that are acceptable in the fields of health products, dietary supplements, functional foods, medical foods or nutritional supplements.

4. A composition according to claim 1 that is beneficial to improving brain cognition, memory, sleep and for preventing and improving Alzheimer's disease, characterized in that At least one or a combination of the following: daily per person dosage range of 50mg to 1000mg of glycerophosphocholine (L-α-GPC), 20mg to 600mg of phosphatidylserine (PS), 20mg to 1000mg of docosahexaenoic acid (DHA), 50mg to 1000mg of tea theanine, and 0.2mg to 10mg of vitamin B1. And acceptable excipients and excipients in the fields of health products, dietary supplements, functional foods, medical foods or nutritional supplements.

5. A composition according to claim 1 that is beneficial to improving brain cognition, memory, sleep and for preventing and improving Alzheimer's disease, characterized in that At least one or a combination of the following: daily per person dosage range of 50mg to 1000mg of glycerophosphocholine (L-α-GPC), 20mg to 600mg of phosphatidylserine (PS), 20mg to 1000mg of docosahexaenoic acid (DHA), 50mg to 1000mg of tea theanine, 0.2mg to 10mg of vitamin B1, and 0.2mg to 10mg of vitamin B2. And acceptable excipients and excipients in the fields of health products, dietary supplements, functional foods, medical foods or nutritional supplements.

6. A composition according to claim 1 that is beneficial to improving brain cognition, memory, sleep and for preventing and improving Alzheimer's disease, characterized in that At least one or a combination of the following: daily per person dosage range of 50mg to 1000mg of glycerophosphocholine (L-α-GPC), 20mg to 600mg of phosphatidylserine (PS), 20mg to 1000mg of docosahexaenoic acid (DHA), 50mg to 1000mg of tea theanine, 0.2mg to 10mg of vitamin B1, 0.2mg to 10mg of vitamin B2, and 0.3mg to 300mg of vitamin B6. And acceptable excipients and excipients in the fields of health products, dietary supplements, functional foods, medical foods or nutritional supplements.

7. A composition according to claim 1 that is beneficial to improving brain cognition, memory, sleep and for preventing and improving Alzheimer's disease, characterized in that At least one or a combination of the following: daily per person dosage range of 50mg to 1000mg of glycerophosphocholine (L-α-GPC), 20mg to 600mg of phosphatidylserine (PS), 20mg to 1000mg of docosahexaenoic acid (DHA), 50mg to 1000mg of tea theanine, 0.2mg to 10mg of vitamin B1, 0.2mg to 10mg of vitamin B2, 0.3mg to 300mg of vitamin B6, and 0.1mg to 1mg of vitamin B9. And acceptable excipients and excipients in the fields of health products, dietary supplements, functional foods, medical foods or nutritional supplements.

8. The composition according to claim 1, which is beneficial to improving brain cognition, memory, sleep and preventing and improving Alzheimer's disease, characterized in that At least one or a combination of the following: daily per person dosage range of 50mg to 1000mg of glycerophosphocholine (L-α-GPC), 20mg to 600mg of phosphatidylserine (PS), 20mg to 1000mg of docosahexaenoic acid (DHA), 50mg to 1000mg of tea theanine, 0.2mg to 10mg of vitamin B1, 0.2mg to 10mg of vitamin B2, 0.3mg to 300mg of vitamin B6, 0.1mg to 1mg of vitamin B9, 0.1mg to 1mg of vitamin B12, and 0.002mg to 0.02mg of vitamin D3. And acceptable excipients and excipients in the fields of health products, dietary supplements, functional foods, medical foods or nutritional supplements.

9. The composition described in claims 1 to 8 is beneficial to improving brain cognition, memory, sleep and preventing and improving Alzheimer's disease, and its product form is a commonly used form acceptable in the field of health products, dietary supplements, functional foods, medical foods or nutritional supplements, including but not limited to tablets, hard capsules, soft capsules, oral solutions, granules, soft candies (candies), powders, beverages, candy products or other oral food forms: such as biscuits, dairy products, sparkling water, etc. These forms of health foods can not only meet people's sensory needs, but also play a health care function.

10. A composition for improving brain cognition, memory, sleep and for preventing and improving Alzheimer's disease as described in claims 1-8. The application of the present invention is preferably used to improve brain cognition, memory, sleep and for preventing and improving the brain health of Alzheimer's patients, but is not limited to, and also includes but is not limited to other applications: enhancing memory and cognitive function, improving learning and information processing ability, resisting fatigue and enhancing physical fitness, relieving anxiety and stabilizing emotions, improving cerebrovascular health, improving sleep quality, protecting nerves and anti-aging, promoting neurotransmitter synthesis, increasing growth hormone secretion, maintaining normal brain function, and combating age-related cognitive decline, etc.

Images